Browsing Tag
Shanghai Henlius Biotech
3 posts
Eisai and Shanghai Henlius Biotech enter Japan-focused licensing pact for serplulimab as PD-1 competition tightens
Discover how Eisai Co., Ltd.’s serplulimab licensing deal with Henlius could reshape Japan’s PD-1 oncology market and investor expectations.
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
Fosun Pharma signs licensing deal with Henlius Biotech for serplulimab
Fosun Pharma has signed an exclusive US licensing agreement with Shanghai Henlius Biotech for commercializing the latter’s serplulimab,…